Get a double shot of capital! Two early stage investors from Nashville, TN are eager to meet their next opportunity in the Bay Area. Joe Cook from Mountain Group Partners and Brian Laden from Tri-Star Health Partners will be visiting JLABS @ SSF on February 23, 2017. Joe and Brian will provide an overview of their unique investment strategies and meet 1-on-1 with pre-selected companies.
Mountain Group Partners invests in early stage companies. Historically, the firm has done everything from work with entrepreneurs on starting companies to investing in Series C/D Preferred financings. Initial investments are typically made during Series A and Series B rounds.
Mountain Group Partners is dedicated to investing in and actively guiding transformational businesses in the Life Sciences and Technology sectors. Within Life Sciences, the firm focuses primarily on Devices, Diagnostics, and Nutraceuticals & Expedited Drug Development. The firm places a premium on those innovations that have existing intellectual property or a novel scientific foundation for building intellectual property. Technology investments focus on Business Services, Consumer and Healthcare Technology, targeting those ideas with quantifiable development risk and a rapid path to market.
Currently, MGP is investing funds from MGC Venture Partners 2013, LP ($50M), Limestone Fund($14M), a fund chosen in 2009 by the State of Tennessee to invest state funds to drive economic growth in Tennessee, and private capital accounts.
TriStar Health Partners invests in early stage healthcare and life sciences companies - biopharma, diagnostics, devices, healthcare IT and technology-enabled healthcare services. TriStar tends to focus on Seed or Series A round opportunities in biopharma and med tech. In the areas of healthcare services and Health IT they put a premium on companies that have a meaningful customer base and a proven, scalable revenue model.
People are the most critical part of any company for TriStar. Strong management and quality co-investors are key as they seek to build strong relationships with successful teams who have aligned goals and compatible personalities. Additionally, they look for unique aspects that help de-risk investments including access to non-dilutive capital, key partnerships, etc. Companies that can directly benefit from the relationships with the hospital systems represented by our partner, the Innovation Institute, are also of particular interest.
TriStar currently manages $40M across two funds and recently announced a partnership with the Innovation Institute and are raising a new fund. This fund will seek those companies that directly affect patient care and increase the value of healthcare delivery.
Select Portfolio examples: NuSirt BioPharma, Castle Biosciences, Clearside Biomedical , Aspire Health, TVA , Cerebrotech , Angel Eye Camera Systems, GenomOncology Nashville Diagnostics (formerly known as "Diagnovus" -select assets sold to Aegis)
Joe Cook, Principal at Mountain Group Partners, and Brian Laden, Co-founder & Managing Director at TriStar Health Partners will be in attendance to provide an overview presentation of their firms area of interest. They will be on hand to meet with a handful of applicants 1-on-1 after the presentation. To be considered for a 1-on-1 meeting complete the information required here. Applications due by January 27, 2017.
10:30am | Registration & Networking
11:00am | Presentation and Q&A
12:00pm | Lunch & Networking
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and been approved. Applications are due January 27, 2017. Apply Here.
About TriStar Health Partners:
TriStar Fund III is a venture growth fund that invests in world-class management teams bringing transformative healthcare innovations to market. The addition of a new strategic partner, The Innovation Institute, will amplify TriStar's ability to quickly produce outstanding returns for our investors by bringing us closer to the healthcare market through the Institute's 5 hospital system partners. Those systems represent over 100 hospitals across 19 states and 27,000 physicians. The Fund will leverage these relationships to enhance diligence, help guide strategy and execution for portfolio companies, and provide strong ties to an early customer base.
About Mountain Group Partners:
Mountain Group Partners takes a unique approach to managing the risk inherent in VC investing. This is driven by the team's background as operators, with a focus on lean and engaged management in addition to active participation in managing portfolio companies. Since Mountain Group Partners' founding in 2002, the firm's Partners have invested in more than 35 companies in its two targeted sectors. The partners of MGP also invest their own capital as well as resources from some large family offices in conjunction with the funds detailed above.
Joe Cook, III | Principal Partner, Mountain Group Partners
Joe Cook, III co-founded Mountain Group Partners (MGP) in 2002. Since that time, MGP has grown from a single family office to a venture capital and leveraged buyout firm, investing on behalf of its own private capital accounts, several large family offices and Limestone Fund. Limestone Fund was chosen in 2009 by the State of Tennessee to invest state funds to drive economic growth in Tennessee. MGP invests in early stage companies in the Life Sciences industry (diagnostics, medical devices, and expedited drug development) and Technology industry (healthcare technology, business services and consumer technology).
Prior to his involvement with MGP, Mr. Cook was a Director, Private Placements in the Investment Banking Group of Robert W. Baird & Co. in Nashville from January 2001 through February 2003. Previously, Mr. Cook was a Vice President in the Investment Banking Group at J.C. Bradford & Co. in Nashville.
Mr. Cook graduated with a B.A. in Economics from Davidson College, and moved to Nashville, TN in 1993.
Mr. Cook currently serves on or has visitation rights to the board of directors of: Castle Biosciences, Cerebrotech, Lineagen, and MiNDERA. Mr. Cook previously served on or had visitation rights to the board of directors of: ABT Molecular Imaging, Clearside Biomedical (NASDAQ: CLSD), Pathfinder Therapeutics, VenX, Diagnovus, and OnFocus Healthcare. Mr. Cook also serves on the Board of Southeast BIO, a regional non-profit organization that fosters the growth of the life sciences industry in the Southeastern U.S., and the Investor Advisory Committee for LaunchTN, a public-private partnership focused on supporting the development of high growth companies in Tennessee.
Connect with Joe:
Brian Laden | Co-founder & Managing Director, TriStar Health Partners
Dr. Laden co-founded TriStar Technology Ventures in 2009, now TriStar Health Partners. Through his role at TriStar, he serves on the Board of Directors for Cerebrotech, GenomOncology, Molecular Sensing, NuSirt Biopharma and Diagnovus (exited) and is an active board observer for TVA and BioStable. He also serves as an adviser to MedCare Investment Funds, a family-based venture fund created by Dr. Jim Leininger. In this capacity Dr. Laden handles special diligence projects for the fund and its portfolio companies. Prior to the founding of TriStar, Dr. Laden served as the Assistant Director in the Office of Technology Transfer and Enterprise Development at Vanderbilt University. That role involved leading various technology transfer functions for Vanderbilt, which included identifying, protecting, marketing and licensing promising new technologies to companies of all stages and sizes, as well as developing collaborative, sponsored R&D and material transfer relationships with industry. He also participated in the office's venture investment and company formation activities. Since beginning as the Chancellor Fund in 2000, Vanderbilt invested a substantial amount of capital in to 30 different Vanderbilt-related companies.
Before getting what his family described as "a real job", Dr. Laden was a postdoctoral researcher in the Department of Biochemistry at Vanderbilt in the lab of Dr. Michael Waterman, where his work focused on structure-function studies of the cytochromes P450. He holds a doctorate in Toxicology from the University of Kentucky, a master's degree in Environmental and Industrial Health from the University of Michigan and an undergraduate degree in biology from Penn State University.
Connect with Brian:
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and lunch will remain open until noon on February 22nd (or sold out).
FREE | Application
FREE | Accepted Companies
Apply to meet one-on-one with representatives from TriStar or Mountain Group Partners. Your application will be reviewed and you will be notified of acceptance on Wednesday, February 8th, 2017. Acceptance of a one-on-one meeting is not guaranteed as all applications must be approved.
About the Meet with... Series:
The purpose of the Meet with Series events sponsored by JLABS is to help start-up entrepreneurs, as well as the academic community, connect with potential partners, such as big pharma or other investment corporations, through one-on-one meetings. It is also a chance for the featured corporation to outline their specific business development goals and clarify what types of products or research they are interested in and how best to approach them to get the partnering process started. Past participants include the Wellcome Trust, Bill & Melinda Gates Foundation, MedImmune Ventures, Mercury Fund, DARPA's Biological Technologies Office, Correlation Ventures, Breakout Labs, New Enterprise Associates, Canaan Partners, Thomas McNerney & Partners, NCI, NCATS, NINDS, Allegory Venture Partners, Clarus Ventures, Johnson & Johnson Innovation, California Institute for Regenerative Medicine, Astellas Venture Management, and OrbiMed.
JLABS @ SSF
329 Oyster Point Blvd - 3rd Floor
South San Francisco, California
Save This Event
When & Where
JLABS Bay Area
JLABS, part of Johnson & Johnson Innovation, LLC, is a network of life science incubators providing emerging companies many of the advantages of being in a big company, without the capital investment. JLABS offers singular bench tops, modular wet lab units and office space on a short-term basis, allowing companies to pay only for the space they need, with an option to quickly expand when they have the resources to do so. Companies residing at JLABS also have access to core research labs hosting specialized capital equipment and shared administrative areas. JLABS is an open innovation model, and the agreement for space does not grant JLABS or Johnson & Johnson Innovation any stake or rights in the companies, nor will the companies have a guaranteed future affiliation with JLABS. The flagship facility is located in San Diego at Janssen's West Coast Research Center, and JLABS has now two established locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility - one in Boston through a collaboration with Lab Central, one in Houston through a collaboration with TMC, and one in Toronto through a collaboration with MaRS. For more information please visit jlabs.jnjinnovation.com.